Zhitong Finance App News, Shanghai Pharmaceutical (601607.SH) issued an announcement. Recently, Shanghai Shangyao Xinyi Pharmaceutical Co., Ltd. (hereinafter referred to as “Shangyao Xinyi”), a subsidiary of the company, received the “Drug Registration Certificate” (Drug Approval Number: Sinopharm Standard H20250067) issued by the China Drug Administration (hereinafter referred to as the “State Drug Administration”), and the drug marketing license application submitted by it was approved by the State Drug Administration.

Zhitong Finance App News, Shanghai Pharmaceutical (601607.SH) issued an announcement. Recently, Shanghai Shangyao Xinyi Pharmaceutical Co., Ltd. (hereinafter referred to as “Shangyao Xinyi”), a subsidiary of the company, received the “Drug Registration Certificate” (Drug Approval Number: Sinopharm Standard H20250067) issued by the China Drug Administration (hereinafter referred to as the “State Drug Administration”), and the drug marketing license application submitted by it was approved by the State Drug Administration.